1991
The Center for Genetic Engineering and Biotechnology begins to produce the recombinant surface antigen of the hepatitis B virus (HBsAg-r), for the manufacture of the preventive vaccine Heberbiovac HB®, a leading product of Cuban biotechnology, with the which Cuba managed to report zero cases of acute hepatitis B infection in children under five years of age, since 2000 and in children under 15 years of age since 2007, thanks to the political will to vaccinate one hundred percent of the child population free of charge since the first hours of birth. In addition, the production of recombinant streptokinase was started for the product Heberkinasa®, a drug that causes rapid lysis of the intracoronary thrombus, prevents ischemic necrosis of the myocardium, improves ventricular function and limits the infarcted area. Heber Biotec S.A. was founded, a marketing company for biotechnological and pharmaceutical products of the Center for Genetic Engineering and Biotechnology (CIGB), registered in more than 35 countries. Heber Biotec S.A. It also commercialized the products of several Cuban scientific-productive companies.